Product image of Linagliptin Zentiva (Linagliptin) supplied by GNH India

Linagliptin Zentiva

Active Ingredient:
Linagliptin
Origin:
EU

Linagliptin Zentiva (Linagliptin)

Linagliptin, the active ingredient in Linagliptin Zentiva, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as a tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to improve glycaemic control when used with diet and exercise.

GNH India supplies Linagliptin Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet the needs of healthcare providers across multiple regions.

Manufacturer / TM Owner

Zentiva Italia S.R.L.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Linagliptin is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus.

  • Type 2 diabetes mellitus (monotherapy): lowers blood glucose and HbA1c when diet and exercise alone are insufficient.
  • Type 2 diabetes mellitus (combination with metformin): provides additional glucose reduction beyond metformin alone.
  • Type 2 diabetes mellitus (add‑on to insulin): helps reduce required insulin dose while maintaining glycaemic control.
  • Type 2 diabetes mellitus (adjunct to other oral agents): offers complementary glucose‑lowering effect in multi‑drug regimens.

How It Works

  • Linagliptin selectively inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, preventing the breakdown of endogenous incretin hormones such as GLP‑1 and GIP. Elevated incretin levels enhance glucose‑dependent insulin secretion from pancreatic β‑cells and suppress glucagon release from α‑cells, resulting in reduced hepatic glucose production and improved post‑prandial glucose control.

Side Effects

Linagliptin is generally well tolerated, but adverse reactions can occur.

Common Side Effects

  • Nasopharyngitis: mild upper‑respiratory infection symptoms.
  • Headache: transient mild to moderate pain.
  • Dizziness: occasional light‑headedness.
  • Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea.
  • Upper respiratory tract infection: cough or sore throat.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain requiring immediate medical attention.
  • Severe hypersensitivity reactions: rash, angioedema, or anaphylaxis.
  • Hepatic dysfunction: elevated liver enzymes or jaundice.
  • Severe hypoglycaemia: especially when combined with insulin or sulfonylureas.
  • Bullous pemphigoid: rare autoimmune skin disorder.

Precautions & Warnings

Before initiating Linagliptin, consider the following safety measures.

  • Renal impairment: monitor kidney function and adjust therapy if necessary.
  • Hepatic impairment: use with caution and observe liver function tests.
  • Hypersensitivity: discontinue the drug if rash, swelling, or anaphylactic signs develop.
  • Pregnancy: safety not established; avoid unless clearly needed.
  • Elderly patients: monitor for dehydration and renal function.
  • Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Linagliptin may interact with other medicines; assess the risk level before co‑administration.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase linagliptin exposure.
  • Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce linagliptin effectiveness.

Moderate Interactions (Monitor Closely)

  • Diuretics: increased risk of dehydration, which can affect glucose control.
  • Insulin or sulfonylureas: heightened risk of hypoglycaemia; dose adjustments may be required.
  • Rifampin (moderate inducer): may modestly lower linagliptin plasma levels.
  • Antihypertensive agents: monitor blood pressure as fluid shifts may occur.

Frequently Asked Questions

Linagliptin Zentiva contains the active ingredient linagliptin, a DPP‑4 inhibitor indicated for the treatment of type 2 diabetes mellitus in adults. It is used to improve glycaemic control when combined with diet and exercise, either alone or as part of combination therapy with other antidiabetic agents.

Linagliptin works by selectively blocking the dipeptidyl peptidase‑4 enzyme, which normally degrades incretin hormones such as GLP‑1 and GIP. By preserving these hormones, linagliptin enhances glucose‑dependent insulin secretion, reduces glucagon release, and lowers hepatic glucose production, leading to better post‑prandial and overall blood‑sugar control.

The specific dose of Linagliptin Zentiva is determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and concomitant therapies. The prescriber will select the appropriate strength and dosing schedule according to current treatment guidelines.

Safety of linagliptin in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Linagliptin shares the same mechanism of action as other DPP‑4 inhibitors but differs in its pharmacokinetic profile; it is primarily excreted unchanged via the bile and gut, requiring no dose adjustment in mild to moderate renal impairment, unlike some alternatives that need renal dosing modifications.

Linagliptin Zentiva tablets should be stored at room temperature, below 25 °C, in the original blister pack or container. Protect them from moisture, excessive heat, and direct sunlight to maintain product stability.

Linagliptin Zentiva is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with water and not chewed or crushed, unless otherwise directed by a healthcare professional.

Serious risks include pancreatitis, severe hypersensitivity reactions such as anaphylaxis, and rare cases of hepatic dysfunction. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash with swelling, or signs of liver injury.

Linagliptin Zentiva should be avoided in individuals with a known hypersensitivity to linagliptin or any component of the formulation. Caution is also advised for patients with severe renal or hepatic impairment, and it is not recommended for use in pregnancy unless clearly indicated by a physician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT